Quoin Pharmaceuticals Files 8-K

TL;DR

Quoin Pharma filed an 8-K on Jan 6, 2025. Details on 'other events' are scarce.

AI Summary

Quoin Pharmaceuticals, Ltd. filed an 8-K on January 6, 2025, reporting other events. The company, formerly known as Cellect Biotechnology Ltd. and Cellect Biomed Ltd., is incorporated in Israel and has its principal executive offices in Ashburn, VA. The filing does not disclose specific details of the 'other events'.

Why It Matters

This 8-K filing indicates that Quoin Pharmaceuticals has reported an event to the SEC, which could be material to investors. However, the lack of specific details in the provided text makes it difficult to assess the immediate impact.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and lacks specific financial or operational details, making it low risk based on the provided information.

Key Players & Entities

• Quoin Pharmaceuticals, Ltd. (company) — Filer of the 8-K
• Cellect Biotechnology Ltd. (company) — Former name of Quoin Pharmaceuticals
• Cellect Biomed Ltd. (company) — Former name of Quoin Pharmaceuticals
• January 6, 2025 (date) — Date of report

FAQ

Filing Documents

• tm252105d1_8k.htm (8-K) — 28KB
• 0001104659-25-001350.txt ( ) — 196KB
• qnrx-20250106.xsd (EX-101.SCH) — 3KB
• qnrx-20250106_lab.xml (EX-101.LAB) — 33KB
• qnrx-20250106_pre.xml (EX-101.PRE) — 22KB
• tm252105d1_8k_htm.xml (XML) — 4KB

01. Other Events

Item 8.01. Other Events. Quoin Pharmaceuticals Ltd. (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced additional positive interim clinical data from one of its ongoing Netherton Syndrome clinical studies. In December 2024, Quoin announced positive data from the first subject dosed twice-daily in Quoin's ongoing open-label study after 6-weeks of dosing with QRX003, marking the midpoint of testing. The Company today shared clinical data for that subject upon completion of testing. The following table illustrates the clear improvements observed for this subject from baseline through 12 weeks of twice-daily dosing with QRX003 across all measured clinical endpoints. Table 1: First Patient Data from Open Label Study Part B- Dosed Twice Daily with QRX003 End Point Baseline 6 weeks 12 weeks M-IASI* 18 4 3 WINRS** 7 4 2 IGA*** Moderate Mild Almost Clear * M-IASI : Modified Ichthyosis Area of Severity Index, a score used to assess the severity and extent of skin symptoms associated with ichthyosis. Lower scores indicate improvement. ** WINRS : Worst Itch Numeric Rating Scale, which measures the severity of itch on an 11-point scale (0 = no itch, 10 = worst imaginable itch). *** IGA : Investigator's Global Assessment, which uses descriptive categories (e.g., clear, mild, moderate, severe) to evaluate the overall severity of Netherton Syndrome symptoms. In addition, the patient satisfaction scores across multiple assessed metrics which were highly positive after 6 weeks of testing demonstrated even further improvement after 12 weeks. No safety concerns were reported for the subject throughout the study.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Date: January 6, 2025 QUOIN PHARMACEUTICALS LTD. By: /s/ Michael Myers Name: Dr. Michael Myers Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR